Skin manifestations of chronic kidney disease

Robles-Méndez, Juan Carlos; Vázquez‐Martínez, Osvaldo; Ocampo‐Candiani, Jorge

doi:10.1016/j.adengl.2015.09.001

Cited by 4 publications

(27 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies show that patients who undergo early total or subtotal parathyroidectomy have a longer survival compared to those who do not undergo the procedure. 55,82 Increased frequency and duration of dialysis with low calcium dialysate controls electrolyte levels and improves this condition. 82 Bisphosphonates such as etidronate and pamidronate have been effective, resulting in pain relief within days and resolution of lesions within weeks.…”

Section: Calcifying Disordersmentioning

confidence: 99%

“…55,82 Increased frequency and duration of dialysis with low calcium dialysate controls electrolyte levels and improves this condition. 82 Bisphosphonates such as etidronate and pamidronate have been effective, resulting in pain relief within days and resolution of lesions within weeks. [82][83][84][85] Sodium thiosulfate may act by displacing calcium from calcium phosphorus, forming calcium thiosulfate, which is more soluble and can be excreted through haemodialysis or by the kidneys.…”

Section: Calcifying Disordersmentioning

confidence: 99%

“…82 Bisphosphonates such as etidronate and pamidronate have been effective, resulting in pain relief within days and resolution of lesions within weeks. [82][83][84][85] Sodium thiosulfate may act by displacing calcium from calcium phosphorus, forming calcium thiosulfate, which is more soluble and can be excreted through haemodialysis or by the kidneys. 82 It has achieved pain relief within days and wound healing within 8 weeks.…”

Section: Calcifying Disordersmentioning

confidence: 99%

“…[82][83][84][85] Sodium thiosulfate may act by displacing calcium from calcium phosphorus, forming calcium thiosulfate, which is more soluble and can be excreted through haemodialysis or by the kidneys. 82 It has achieved pain relief within days and wound healing within 8 weeks. 86 It is important to monitor for the side effect of metabolic acidosis when using this drug.…”

Section: Calcifying Disordersmentioning

confidence: 99%

“…68,89 Treatment of PCT includes avoiding triggers such as alcohol, hepatotoxic medications, and sun exposure as well as using sunscreen, particularly zinc oxide, and titanium oxide-based sunscreen. 50,82 Decreasing iron overload is effective for symptom management and can be achieved by a combination of erythropoiesis stimulating agents and small volume phlebotomy (50-100 mL once or twice weekly) to decrease hepatic iron stores. 50 The mechanism of iron therapy is twofold because iron induces the enzyme 5-aminolevulinate synthase, which suppresses uroporphyrinogen decarboxylase and because iron increases conversion of uroporphyrinogen into porphyrins.…”

Section: Bullous Dermatosesmentioning

confidence: 99%

See 4 more Smart Citations

Dermatologic manifestations in end stage renal disease

Blaha

Nigwekar

Combs

et al. 2018

Hemodialysis International

View full text Add to dashboard Cite

Skin manifestations are commonly seen in end stage renal disease (ESRD). Skin involvement in this population can be extensive and dramatically worsen quality of life. Close observation of the skin and nails of ESRD patients by clinicians allows for timely diagnosis and treatment, which ultimately improves quality of life and reduces mortality. In this article we focus on the cutaneous changes most commonly seen in ESRD patients. PubMed/Medline database search was done for published literature on skin manifestations in ESRD patients. All the available literature was reviewed and relevant articles were used to discuss about clinical features, pathogenesis, histology and treatment of each skin disorder in ESRD patients. Most commonly encountered skin manifestations in patients with ESRD are pruritus, xerosis, pigmentation changes, nail changes, perforating disorders, calcifying disorders, bullous dermatoses and nephrogenic systemic fibrosis. Skin manifestations in ESRD can be difficult to treat and multiple comorbidities in this patient population can exacerbate these disorders. Many of the treatment options are experimental with evidence largely derived from the case reports and small clinical trials. More large‐scale trials are needed to firmly establish evidence based treatment guidelines. Prompt evaluation and management of these disorders improve morbidity and quality of life in ESRD patients.

show abstract

Section: Calcifying Disordersmentioning

confidence: 99%

Section: Calcifying Disordersmentioning

confidence: 99%

Section: Calcifying Disordersmentioning

confidence: 99%

Section: Calcifying Disordersmentioning

confidence: 99%

Section: Bullous Dermatosesmentioning

confidence: 99%

See 3 more Smart Citations

Dermatologic manifestations in end stage renal disease

Blaha

Nigwekar

Combs

et al. 2018

Hemodialysis International

View full text Add to dashboard Cite

show abstract

Dermatological manifestations in children with chronic kidney disease: a study from a North Indian tertiary care institute

et al. 2021

View full text Add to dashboard Cite

Summary Background Dermatological manifestations due to impaired renal function in children with chronic kidney disease (CKD) are diverse and are an important cause of morbidity. Aim To determine the prevalence of dermatological manifestations in predialysis children with different stages of CKD and its association with various metabolic parameters. Methods This cross‐sectional observational study was conducted in 200 predialysis children with CKD stages 1–5 and 200 age‐ and sex‐matched healthy controls (HCs). Detailed dermatological examination was performed to check for any pathological/physiological changes in the skin, mucosa, hair and nails, and changes were recorded in a predesigned proforma. Results The median age of cases and HCs was 60.50 months (76.5% males) and 62 months (78.5% males) respectively. Skin manifestations were seen in 189 (94.5%) cases and 156 (78%) HCs (P < 0.001). The most common skin manifestation among cases was pallor (75.5%, P < 0.001) followed by xerosis (48.5%, P < 0.001), atopic diathesis (41.5%) and pruritus (13%, P < 0.001), while among HCs, the most common skin manifestation was atopic diathesis (46%), followed by pallor (24%) and xerosis (14%). Xerosis was found to be significantly associated with higher serum creatinine levels (P = 0.04) and hypocalcaemia (P = 0.03). There was no significant association found between pruritus and serum creatinine. Conclusion Xerosis was significantly associated with higher levels of creatinine and hypocalcaemia. Timely recognition of these symptoms and proper management can improve the quality of life in children with CKD.

show abstract

Chronic kidney disease‐associated pruritus in patients undergoing hemodialysis: Xerosis and topical therapy

Krismi

Danarti

Setiabudi

et al. 2023

Hemodialysis International

View full text Add to dashboard Cite

Chronic kidney disease‐associated pruritus (CKD‐aP) is a common and distressing symptom for patients with CKD and a difficult challenge for nephrologists and dermatologists. Recent results showed the multifactorial nature of the pathophysiology, and therapeutic trials were only successful in certain subsets of patients. The clinical manifestations are varied, with xerosis being the most common dermatological manifestation and correlated with the intensity of CKD‐aP. A better understanding of the pathophysiology of xerosis in CKD‐aP and appropriate topical treatment could correct xerosis to reduce the intensity of CKD‐aP and improve the patient's quality of life.

show abstract

Skin manifestations of chronic kidney disease

Cited by 4 publications

References 48 publications

Dermatologic manifestations in end stage renal disease

Dermatologic manifestations in end stage renal disease

Dermatological manifestations in children with chronic kidney disease: a study from a North Indian tertiary care institute

Chronic kidney disease‐associated pruritus in patients undergoing hemodialysis: Xerosis and topical therapy

Contact Info

Product

Resources

About